Long‐term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: An open, observational, extension study of a three‐month, randomized, placebo‐controlled trial

Infliximab therapy in AS patients resulted in a rapid and significant improvement in BASDAI scores (>50% improvement) and a durable response for 1 year. The safety profile of infliximab in AS was comparable to that observed in the postmarketing experience for the approved indications.